程序化与自然冻融胚胎移植周期的产科和围产期结局:系统综述与Meta分析
该系统综述与Meta分析检索截至2021年11月1日的文献,比较程序化(激素替代治疗)与自然冻融胚胎移植方案的产科和围产期结局。程序化方案与妊娠期高血压疾病、子痫前期、产后出血和剖宫产风险显著升高相关;但经混杂因素校正后,仅妊娠期高血压疾病、子痫前期、产后出血和剖宫产仍保持显著关联。因方法学弱点,无法据此给出临床实践推荐。
要点
- 程序化冻融胚胎移植与妊娠期高血压疾病风险升高相关(OR 1.90,95%CI 1.64-2.20)。
- 程序化方案与子痫前期(OR 2.11)、产后出血(OR 2.53)、剖宫产(OR 1.62)风险升高相关。
- 经混杂因素校正后,仅妊娠期高血压疾病、子痫前期、产后出血和剖宫产仍与激素替代治疗显著相关。
核心结论
- 激素替代治疗子宫内膜准备方案与较差的产科和围产期结局相关。
- 由于方法学弱点,无法据此给出临床实践推荐。
- 需要设计良好的前瞻性研究来确立安全的冻融胚胎移植子宫内膜准备策略,以限制对产科和围产期并发症高危女性的叠加风险。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、MEDLINE、Embase和Scopus自建库至2021年11月1日的文献。
- 纳入报告至少两种子宫内膜准备方案(程序化、完全自然、改良自然、刺激周期)产科和/或围产期结局的随机对照试验、队列研究和病例对照研究。
- 使用纽卡斯尔-渥太华质量评估量表评估偏倚风险,并使用推荐分级的评估、制定与评价(GRADE)方法评估证据质量。
- 注册号:CRD42021249927。
主要发现
- 程序化冻融胚胎移植与自然周期(完全自然+改良自然)冻融胚胎移植相比,妊娠期高血压疾病风险升高(12项研究,OR 1.90,95%CI 1.64-2.20,P<0.00001,I²=50%,极低质量)。
- 程序化冻融胚胎移植与自然周期冻融胚胎移植相比,子痫前期风险升高(8项研究,OR 2.11,95%CI 1.87-2.39,P<0.00001,I²=29%,低质量)。
- 程序化冻融胚胎移植与自然周期冻融胚胎移植相比,产后出血风险升高(6项研究,OR 2.53,95%CI 2.19-2.93,P<0.00001,I²=0%,低质量)。
- 程序化冻融胚胎移植与自然周期冻融胚胎移植相比,剖宫产风险升高(12项研究,OR 1.62,95%CI 1.53-1.71,P<0.00001,I²=48%,极低质量)。
- 经混杂因素校正后合并OR,激素替代治疗子宫内膜准备仅在妊娠期高血压疾病、子痫前期、产后出血(低质量)和剖宫产(极低质量)的所有亚组分析中保持显著关联。
关键数值与推荐
- 妊娠期高血压疾病:12项研究,OR 1.90,95%CI 1.64-2.20,P<0.00001,I²=50%,极低质量。
- 子痫前期:8项研究,OR 2.11,95%CI 1.87-2.39,P<0.00001,I²=29%,低质量。
- 产后出血:6项研究,OR 2.53,95%CI 2.19-2.93,P<0.00001,I²=0%,低质量。
- 剖宫产:12项研究,OR 1.62,95%CI 1.53-1.71,P<0.00001,I²=48%,极低质量。
- 经混杂因素校正后,激素替代治疗与妊娠期高血压疾病、子痫前期、产后出血(低质量)和剖宫产(极低质量)保持显著关联。
临床怎么用
- 原文未据此给出推荐。
- 作者指出,由于方法学弱点,无法做出临床实践推荐。
- 作者认为需要设计良好的前瞻性研究来确立安全的冻融胚胎移植子宫内膜准备策略。
局限性
- 主要局限性涉及研究间异质性:(i)激素替代治疗的时间和剂量;(ii)移植时胚胎阶段;(iii)纳入植入前遗传学检测周期。
- 为处理异质性,研究仅合并针对特定可能混杂因素校正后的OR进行亚组分析。
- 由于方法学弱点,无法做出临床实践推荐。
- 需要设计良好的前瞻性研究来确立安全的子宫内膜准备策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there an association between the different endometrial preparation protocols for frozen embryo transfer (FET) and obstetric and perinatal outcomes? SUMMARY ANSWER: Programmed FET protocols were associated with a significantly higher risk of hypertensive disorders of pregnancy (HDP), pre-eclampsia (PE), post-partum hemorrhage (PPH) and cesarean section (CS) when compared with natural FET protocols. WHAT IS KNOWN ALREADY: An important and growing source of concern regarding the use of FET on a wide spectrum of women, is represented by its association with obstetric and perinatal complications. However, reasons behind these increased risks are still unknown and understudied. STUDY DESIGN, SIZE, DURATION: Systematic review with meta-analysis. We systematically searched PubMed, MEDLINE, Embase and Scopus, from database inception to 1 November 2021. Published randomized controlled trials, cohort and case control studies were all eligible for inclusion. The risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. The quality of evidence was also evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. PARTICIPANTS/MATERIALS, SETTING, METHODS: Studies were included only if investigators reported obstetric and/or perinatal outcomes for at least two of the following endometrial preparation protocols: programmed FET cycle (PC-FET) (i.e. treatment with hormone replacement therapy (HRT)); total natural FET cycle (tNC-FET); modified natural FET cycle (mNC-FET); stimulated FET cycle (SC-FET). MAIN RESULTS AND THE ROLE OF CHANCE: Pooled results showed a higher risk of HDP (12 studies, odds ratio (OR) 1.90; 95% CI 1.64-2.20; P < 0.00001; I2 = 50%) (very low quality), pregnancy-induced hypertension (5 studies, OR 1.46; 95% CI 1.03-2.07; P = 0.03; I2 = 0%) (very low quality), PE (8 studies, OR 2.11; 95% CI 1.87-2.39; P < 0.00001; I2 = 29%) (low quality), placenta previa (10 studies, OR 1.27; 95% CI 1.05-1.54; P = 0.01; I2 = 8%) (very low quality), PPH (6 studies, OR 2.53; 95% CI 2.19-2.93; P < 0.00001; I2 = 0%) (low quality), CS (12 studies, OR 1.62; 95% CI 1.53-1.71; P < 0.00001; I2 = 48%) (very low quality), preterm birth (15 studies, OR 1.19; 95% CI 1.09-1.29; P < 0.0001; I2 = 47%) (very low quality), very preterm birth (7 studies, OR 1.63; 95% CI 1.23-2.15; P = 0.0006; I2 = 21%) (very low quality), placenta accreta (2 studies, OR 6.29; 95% CI 2.75-14.40; P < 0.0001; I2 = 0%) (very low quality), preterm premature rupture of membranes (3 studies, OR 1.84; 95% CI 0.82-4.11; P = 0.14; I2 = 61%) (very low quality), post-term birth (OR 1.90; 95% CI 1.25-2.90; P = 0.003; I2 = 73%) (very low quality), macrosomia (10 studies, OR 1.18; 95% CI 1.05-1.32; P = 0.007; I2 = 45%) (very low quality) and large for gestational age (LGA) (14 studies, OR 1.08; 95% CI 1.01-1.16; P = 0.02; I2 = 50%) (very low quality), in PC-FET pregnancies when compared with NC (tNC + mNC)-FET pregnancies. However, after pooling of ORs adjusted for the possible confounding variables, the endometrial preparation by HRT maintained a significant association in all sub-analyses exclusively with HDP, PE, PPH (low quality) and CS (very low quality). LIMITATIONS, REASONS FOR CAUTION: The principal limitation concerns the heterogeneity across studies in: (i) timing and dosage of HRT; (ii) embryo stage at transfer; and (iii) inclusion of preimplantation genetic testing cycles. To address it, we undertook subgroup analyses by pooling only ORs adjusted for a specific possible confounding factor. WIDER IMPLICATIONS OF THE FINDINGS: Endometrial preparation protocols with HRT were associated with worse obstetric and perinatal outcomes. However, because of the methodological weaknesses, recommendations for clinical practice cannot be made. Well conducted prospective studies are thus warranted to establish a safe endometrial preparation strategy for FET cycles aimed at limiting superimposed risks in women with an 'a priori' high-risk profile for obstetric and perinatal complications. STUDY FUNDING/COMPETING INTEREST(S): None. REGISTRATION NUMBER: CRD42021249927.
引用
- Busnelli A, Schirripa I, Fedele F, et al. Obstetric and perinatal outcomes following programmed compared to natural frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Hum Reprod. 2022. PMID: 35553678. doi:10.1093/humrep/deac073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。